{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:20:07Z","timestamp":1792794007471,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03682-5","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:44:04Z","timestamp":1784357044000},"page":"4684-4700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Statins in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Han","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6739","authenticated-orcid":false,"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"issue":"2","key":"3682_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516\u201337.","journal-title":"J Hepatol"},{"key":"3682_CR2","doi-asserted-by":"crossref","unstructured":"Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on the management of liver cirrhosis. J Dig Dis. 2024;25(6):332\u201352.","DOI":"10.1111\/1751-2980.13294"},{"issue":"2","key":"3682_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406\u201360.","journal-title":"J Hepatol"},{"issue":"9","key":"3682_CR4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","volume":"64","author":"G Marrone","year":"2015","unstructured":"Marrone G, Maeso-D\u00edaz R, Garc\u00eda-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64(9):1434\u201343.","journal-title":"Gut"},{"issue":"1","key":"3682_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"J Trebicka","year":"2007","unstructured":"Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242\u201353.","journal-title":"Hepatology"},{"issue":"5","key":"3682_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"J Bosch","year":"2020","unstructured":"Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020;69(5):953\u201362.","journal-title":"Gut"},{"issue":"3","key":"3682_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749\u201355.","journal-title":"Gastroenterology"},{"issue":"7","key":"3682_CR8","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.14309\/ajg.0000000000003689","volume":"121","author":"R Rana","year":"2026","unstructured":"Rana R, Tabish M, Agarwal S, et al. Simvastatin addition to standard of care improves long-term survival in patients with cirrhosis after variceal bleed: an open label randomized controlled trial. Am J Gastroenterol. 2026;121(7):1638\u201349.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"3682_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2024.27441","volume":"333","author":"E Pose","year":"2025","unstructured":"Pose E, Jimenez C, Zaccherini G, et al. Simvastatin and rifaximin in decompensated cirrhosis: a randomized clinical trial. JAMA. 2025;333(10):864\u201374.","journal-title":"JAMA"},{"issue":"8","key":"3682_CR10","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1097\/MCG.0000000000001732","volume":"56","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhang Q, Li S, Xie B. Simvastatin is efficacious in treating cirrhosis: a meta-analysis. J Clin Gastroenterol. 2022;56(8):e303\u201312.","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"3682_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70326","volume":"45","author":"E Abdulrazzak","year":"2025","unstructured":"Abdulrazzak E, Fakhoury B, Jaan A, et al. Statin therapy and portal pressure reduction in cirrhosis: a systematic review and meta-analysis. Liver Int. 2025;45(10):e70326.","journal-title":"Liver Int"},{"issue":"6","key":"3682_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/apt.70526","volume":"63","author":"BF Moraes","year":"2026","unstructured":"Moraes BF, Leite G, Silveira IB, et al. Statin therapy independently reduces mortality and liver complications in patients with cirrhosis: an updated systematic review and meta-analysis. Aliment Pharmacol Ther. 2026;63(6):778\u201394.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3682_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.","journal-title":"PLoS Med"},{"key":"3682_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3682_CR15","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions (current version) 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current. Accessed 25 Dec 2025."},{"key":"3682_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"3682_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes JG, Albillos A, Ba\u00f1ares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651\u20138.","journal-title":"Gastroenterology"},{"issue":"11","key":"3682_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","volume":"47","author":"P Pollo-Flores","year":"2015","unstructured":"Pollo-Flores P, Soldan M, Santos UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis. 2015;47(11):957\u201363.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"3682_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160-70.e3.","journal-title":"Gastroenterology"},{"issue":"1","key":"3682_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","volume":"30","author":"S Bishnu","year":"2018","unstructured":"Bishnu S, Ahammed SM, Sarkar A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol. 2018;30(1):54\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3682_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.12688\/f1000research.13915.1","volume":"7","author":"N Elwan","year":"2018","unstructured":"Elwan N, Salah R, Hamisa M, Shady E, Hawash N, Abd-Elsalam S. Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial. F1000Res. 2018;7:256.","journal-title":"F1000Res"},{"issue":"1","key":"3682_CR22","doi-asserted-by":"publisher","first-page":"020","DOI":"10.29328\/journal.acgh.1001010","volume":"3","author":"SK Jha","year":"2019","unstructured":"Jha SK, Saharawat K, Keshari R, Jha P, Purkayastha S, Ranjan R. Addition of simvastatin to carvedilol and endoscopic variceal ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child Pugh C class. Annal Clin Gastroenterol and Hepatol. 2019;3(1):020\u20136.","journal-title":"Annal Clin Gastroenterol and Hepatol"},{"issue":"1","key":"3682_CR23","first-page":"86","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu H, Lei Z, Chen Y. The clinical efficacy of statins for portal hypertension in patients with hepatitis\u00a0B virus-related cirrhosis (Chinese). Chin Hepatol. 2019;24(1):86\u20139.","journal-title":"Chin Hepatol"},{"issue":"1","key":"3682_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","volume":"5","author":"E Pose","year":"2020","unstructured":"Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase\u00a02 trial. Lancet Gastroenterol Hepatol. 2020;5(1):31\u201341.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3682_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","volume":"115","author":"R Vijayaraghavan","year":"2020","unstructured":"Vijayaraghavan R, Jindal A, Arora V, Choudhary A, Kumar G, Sarin SK. Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial. Am J Gastroenterol. 2020;115(5):729\u201337.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"3682_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000332","volume":"7","author":"TM Kronborg","year":"2023","unstructured":"Kronborg TM, Schierwagen R, Tro\u0161t K, et al. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol Commun. 2023;7(12):e0332.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3682_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/HEP.0000000000001148","volume":"82","author":"E Alvarado-Tapias","year":"2025","unstructured":"Alvarado-Tapias E, Brujats A, Puente A, et al. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to \u03b2-blockers: a double-blind, placebo-controlled, randomized-trial. Hepatology. 2025;82(1):140\u201354.","journal-title":"Hepatology"},{"issue":"10","key":"3682_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.53350\/pjmhs22161078","volume":"16","author":"BR Malik","year":"2022","unstructured":"Malik BR, Asghar U, Anwar R, Mehmood-Ul-Hassan S, Salim MW. Effect of simvastatin on hepatic venous portal gradient for maintenance of lipid profile of liver cirrhosis patients. Pak J Med Health Sci. 2022;16(10):78\u201380.","journal-title":"Pak J Med Health Sci"},{"issue":"4","key":"3682_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u201374.","journal-title":"J Hepatol"},{"issue":"6","key":"3682_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/apt.12430","volume":"38","author":"C Motzkus-Feagans","year":"2013","unstructured":"Motzkus-Feagans C, Pakyz AL, Ratliff SM, Bajaj JS, Lapane KL. Statin use and infections in Veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38(6):611\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"3682_CR31","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807\u201324."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03682-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:46Z","timestamp":1790609986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03682-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3682"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03682-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xingshun Qi is an editorial board member of\n                      Advances in Therapy\n                      . Xingshun Qi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Han Deng, Ran Wang, Yuhang Yin, Rui Zhang, Xiangbo Xu, and Xiaohui Fang have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}